VCU Massey Cancer Center | Strategic Alliance Partners

A National Cancer Institute-designated cancer center in Richmond, Va., VCU Massey Cancer Center conducts basic, translational, clinical and population sciences cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. Its 1,000-plus researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately cure cancer.

Latest from VCU Massey Cancer Center

Dr. Geyer Discusses Pertuzumab in HER2+ Breast Cancer

December 29, 2018

Video

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.

Dr. Geyer on the Rationale for the KATHERINE Trial in HER2-Positive Breast Cancer

December 11, 2018

Video

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the rationale and results of the phase III KATHERINE trial in HER2-positive breast cancer.

VCU Explores Novel Combos for Solid Tumors

July 03, 2017

Article

Studies conducted at VCU Massey Cancer Center in Richmond, Virginia, over the past 7 years have developed the therapeutic combination of pemetrexed and sorafenib (Nexavar) from the bench to the bedside, and now into phase II clinical trial evaluation.

BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma

April 17, 2017

Article

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

Computer Model Personalizes Donor Selection for Stem Cell Transplants

August 31, 2016

Article

Investigators at Virginia Commonwealth University Massey Cancer Center are developing dynamical models that may allow clinicians to move beyond simple human leukocyte antigen matching to personalize immunosuppressive regimens and thus improve donor selection.

Diffusion-Weighted MRI Studies Explored at VCU Massey Cancer Center

March 14, 2016

Article

The Department of Radiation Oncology at Virginia Commonwealth University Massey Cancer Center has long been at the forefront worldwide in the development of various radiation therapy technologies that are now considered standard and have become widely available.

Upcoming Approvals, Combinations Will Transform CLL Treatment

February 25, 2016

Article

Victor Y. Yazbeck, MD, discusses the potential for venetoclax and idelalisib, both as single agents and in combination with other agents, and what questions remain regarding both therapies in CLL.

Olaparib Studies Put Focus on BRCA-Positive Breast Cancers

January 30, 2016

Article

The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in women’s health research.

VCU Massey Cancer Center Joins OncLive's® Strategic Alliance Partnership Program

June 17, 2015

Article

OncLive® announced an addition to its vibrant Strategic Alliance Partnership program today as VCU Massey Cancer Center signed onto the program's mission to raise awareness of cancer treatment and research.